Gilead Sciences (GILD) Misses Q4 EPS by 37c, Offers Guidance
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.30, $0.37 worse than the analyst estimate of $1.67. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.71 billion.
GUIDANCE:
Gilead Sciences sees FY2020 EPS of $6.05-$6.45, versus the consensus of $7.01.
Product Sales |
| $21,800 - $22,200 |
Non-GAAP |
|
|
Product Gross Margin |
| 86% - 87% |
R&D Expenses |
| Mid-single digit percentage growth |
SG&A Expenses |
| Mid-single digit percentage growth |
Operating Income |
| $10,100 - $10,800 |
Effective Tax Rate |
| ~ 21% |
Diluted EPS |
| $6.05 - $6.45 |
GAAP Diluted EPS |
| $5.15 - $5.55 |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.